Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural antioxidant with cardiovascular and cancer preventive properties, that is currently at the stage of pre-clinical studies for human cancer prevention. Beside its known effects on protein coding genes, one possible mechanism for resveratrol protective activities is by modulating the levels of non-coding RNAs. Here, we analyzed the effects of resveratrol on microRNA populations in human SW480 colon cancer cells. We establish that resveratrol treatment decreases the levels of several oncogenic microRNAs targeting genes encoding Dicer1, a cytoplasmic RNase III producing mature microRNAs from their immediate precursors, tumor suppressor factors such as PDCD4 or PTEN, as well as key effectors of the TGF signaling pathway, while increasing the levels of miR-663, a tumor-suppressor microRNA targeting TGF1 transcripts. We also show that, while upregulating several components of the TGF signaling pathway such as TGF receptors type I (TGFR1) and type II (TGFR2), resveratrol decreases the transcriptional activity of SMADs, the main effectors of the canonical TGF pathway. Our results establish that protective properties of resveratrol may arise at least in part from its capability to modify the composition of microRNA populations in cells, and suggest that the manipulation of the levels of key microRNAs, such as miR-663, may help to potentiate the anti-cancer and anti-metastatic effects of resveratrol.
Introduction
Colorectal cancer (CRC) is the third most common malignancy and the fourth biggest cause of cancer mortality worldwide [1, 2] . Despite the increased use of screening strategies such as fetal occult blood testing, sigmoidoscopy and colonoscopy, more than one third of patients with colorectal cancer will ultimately develop metastatic disease [2] . It is now widely accepted that genetic factors play key roles in the predisposition to colorectal cancer development and progression. Thus, more than 11% of patients with colorectal cancer have at least one first degree relative with the same disease [3] , however twin studies suggest that roughly 35% of CRCs are inherited [4] . Understanding the genes and pathways that cause CRC are thus of greatest interest, for they will allow to improve both the diagnoses and prognoses of the disease as well as to optimize its prevention and treatment. The genetic basis of familial CRC has been actively analyzed in the last decades, and the various CRC sub-types linked to several gene mutations responsible for initiating them [5] . For example, Lynch syndrome, formerly known as hereditary non-polyposis CRC, is characterized by rapid progression of colorectal tumors, related to germline mutation of one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2 [6] .
In addition, germline mutations in APC, a gene encoding a gatekeeper that acts as a negative regulator of the WNT signaling pathway, were initially found in Familial Adenomatous Polyposis (FAP), a syndrome that accounts for less than 1% of CRC in the United States, but then somatic mutations of APC have been found in the great majority of sporadic CRCs [6] .
Indeed, activating mutations of the canonical WNT signaling pathway, which signals through the nuclear relocalization of -CATENIN, have been found in more than 90% of CRCs [7] . Once in the nucleus, -CATENIN functions as a cofactor for transcription factors of the T-cell factor/lymphoid enhancing factor (TCF/LEF) family, which regulate the transcription of genes mainly determining cell fate and regulating cell proliferation [7] .
On the other hand, the TGF signaling pathway is involved in a number of biological processes, including cell proliferation, differentiation, migration and apoptosis [8] . It is one of the most commonly altered cellular signaling pathways in human cancers [9] . TGF signaling is initiated by the binding of TGF ligands to type II receptors (TGFR2). Three TGF isoforms (TGF1, TGF2 and TGF3) are expressed in mammalian epitheliums, each being encoded by a unique gene and expressed in both a tissue-specific and developmentally regulated manner, with TGF1 being the most abundant and ubiquitously expressed isoform. Once bound by TGF, TGFR2 recruits, phosphorylates and thus activates of the type I TGF receptor (TGFR1).
TGFR1 then phosphorylates two transcriptional regulators, namely SMAD2 and SMAD3, which subsequently bind to SMAD4. This results in the nuclear translocation of SMAD complexes, allowing SMADs to interact with transcription factors controlling the expression of a multitude of TGF responsive genes [10] . TGF1 is usually considered a tumor suppressor, due to its cytostatic activity in epitheliums. However, on advanced stages of tumors, TGF1 behaves as a tumor promoter, due to its capability to enhance angiogenesis, epithelial-to-mesenchymal transition, cell motility and metastasis [11] [12] [13] . Not only the expression of TGF1 in both tumor and plasma was found to be significantly higher in patients with metastasic colorectal cancer, but increasing colorectal tumor stage was correlated with higher TGF1 expression in tumor tissues [14] .
MicroRNAs (miRNAs) are short non-coding RNAs which regulate the translation and/or degradation of target messenger RNAs, and whose molecular malfunctions are associated with cancers [15, 16] . Depending on the effects of their downregulation or over-expression, miRNAs have been described either as oncogenic (onco-miRs) or tumor suppressors. For example, genomic amplification and over-expression of miR-17-92 miRNAs is found in B-cell lymphomas as well as in breast and lung cancers [15, 16] . MiR-21 is over-expressed in several cancers, including CRCs, gliomas, as well as breast, gastric, prostate, pancreas, lung, thyroid and cervical cancers [17] . On the other hand, let-7 miRNAs, frequently downregulated in cancers like lung, colon or other solid tumors, are therefore considered as tumor suppressor miRNAs in these types of cancers [15] . Also, miR-15 and miR-16-1 suppress tumorigenicity by inhibiting cell proliferation and promoting apoptosis of cancer cells [18] . Beside miR-21, several miRNAs are overexpressed in CRCs, such as for example miR-17, miR-25, miR-26a or miR-181a [19, 20] .
Furthermore, several miRNAs, including miR-21, have been shown to activate metastasis by acting on multiple signaling pathways and targeting various proteins that are key players in this process [19, 21] .
Resveratrol (trans-3,4',5-trihydroxystilbene) is a dietary polyphenolic, non-flavonoid antioxidant derived from grapes, berries, peanuts, and other plant sources. Resveratrol has various health benefits, such as cardiovascular and cancer preventive properties [22] [23] [24] , and it is currently at the stage of pre-clinical studies for human cancer prevention [24, 25] . Resveratrol induces apoptosis by up-regulating pro-apoptotic genes while simultaneously down-regulating anti-apoptotic genes. Resveratrol induces the redistribution of CD95 and other death receptors in lipid rafts, thus contributing to their sensitization to death receptor agonists [26] . In addition, resveratrol causes growth arrest at G1 and G1/S phases by inducing the expression of CDK inhibitors p21/CDKN1A and p27/CDKN1B [23] . However, the molecular bases for resveratrol effects remain unclear.
Here, we address the effects of resveratrol treatment on miRNA populations from human SW480 cells. We show that resveratrol modulates the levels of miRNAs targeting both oncogenes and tumor suppressor genes, which provides a rational for manipulating the levels of miRNAs depending on the nature and the stage of tumors to optimize the anti-tumors effects of resveratrol.
Materials and methods

Micro-array analyses
RNAs extracted with TRIzol (Invitrogen, Carlsbad, California, USA) were subsequently subjected to DNase digestion (Turbo-DNase from Ambion, Invitrogen, Carlsbad, California, USA). MiRNA micro-array analyses were done at the Ohio State University micro-array facility.
Data were submitted to MIAME database with the accession numbers to be received after confirmation.
Cell culture, transfection and treatments
SW480 cells were maintained in culture following standard procedures. Transfections were done using Lipofectamine 2000 (Invitrogen). Cells were treated for 14 hours with either the vehicle (ethanol) or resveratrol 50 M (Sigma-Aldrich, Saint Louis, Missouri, USA). Whenever needed, cells were either mock-treated or stimulated for 14 hours with 100 ng/ml TGF1 (Invitrogen).
Preparation of clones and subclones
The 307 nt-long 3'-UTR (untranslated region) of the 
Mutagenesis
The two sets of overlapping miR-663 target sites in TGF1 3'-UTRs, respectively containing three and two miR-663 sites, (site 663-1: CCCCGCCCCGCCCCGCC, starting at nt 8, and site 663-2: CCCCGCCCCGCC, starting at nt 43) were respectively mutated to M663-1 (CGGCGCGCGGCCGGGCC) and M663-2 (GCCGCGCCGCGG) using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, Agilent Technologies, Inc., Santa Clara, California, USA). M663-1,2 mutant carry both mutations simultaneously.
Luciferase assays
SW480
(1 x 10 6 ) in 6-well plates were transfected with 0. Valencia, California, USA). This kit is designed to monitor the activity of the canonical TGF-induced signal transduction pathway, i.e., to give a measure of the rate of SMAD2 and/or SMAD3 nuclear transcriptional activity in conjunction with SMAD4 on a reporter construct containing a functional SMAD binding site.
RNase-protection assays
Assays were performed using the mirVana miRNA Probe Construction Kit and the mirVana miRNA Detection Kit from Ambion. RNAs were incubated overnight at 46 °C in the presence of 8 x 10 4 cpm of [ 32 P]-labelled antisense RNA probe and then digested for 40 minutes at 37 °C using a 1/50 dilution of the provided RNAse A/RNase T1 solution. The relative intensities of the bands were determined using the Adobe Photoshop software (Adobe Systems Incorporated, San Jose, California, USA).
Western blots
Anti-TGF1 and anti-SMAD3 antibodies were from Cell Signaling Technology (Danvers, Massachusetts, USA). Anti-TGFR1, anti-TGFR2, anti-SMAD7, anti-PDCD4 and anti-E-CADHERIN antibodies were from Abcam (Abcam Inc., Cambridge, Massachusetts, USA). Anti-PTEN and anti-GAPDH antibodies were from Santa Cruz Biotechnology (Santa Cruz, California, USA). The relative intensities of the bands on Western blots were determined using the Adobe Photoshop software.
Statistical analysis
Results are expressed as mean ± S.D. The statistical significance of the results was determined by Student t tests using the Microsoft Excel software (Microsoft Campus, Redmond, Washington, USA).
Results
Resveratrol modulates the levels of miRNAs targeting known tumor suppressors as well as components of the TGF signaling pathway
MiRNA micro-arrays (MIAME accession number) showed that a 14 hours resveratrol treatment of SW480 cells significantly (P < 0.05) increased the levels of 22 miRNAs while decreasing those of 26 other miRNAs ( Table 1 ). The changes in miRNA levels were generally limited, with a few exceptions such as a 17 and 11 fold upregulation of miR-146b-5p and miR-1,
respectively. This suggests that resveratrol effects on miRNA populations are not global, but rather miRNA-specific. Several miRNAs downregulated by resveratrol, as for example miR-17, miR-21, miR-25, or miR-92a-2, are generally considered as onco-miRs [15, 16] and are known to be overexpressed in CRCs [19, 20] . Surprisingly, miR-16-1 was also downregulated by resveratrol, while usually working along miR-15 to suppress tumorigenicity by inhibiting cell proliferation and promoting apoptosis of cancer cells [18] .
In silico analysis using TargetScan (http://www.targetscan.org/) showed that several of miRNAs under resveratrol control potentially target known tumor suppressor genes, such as components of the mismatch repair machinery (MLH3, MSH2 and MSH3), PDCD4 and PTEN, as well as several effectors and regulators of the TGF signaling pathway ( Table 2) . Of note, the same miRNAs may also potentially target DICER1 transcripts, with encode the RNase III producing mature miRNas from their immediate precursors in the cytoplasm. A majority of the miRNAs potentially targeting the above targets were downregulated by resveratrol ( Table 1) .
Altogether, these results indicate that some of resveratrol antitumor properties may arise from its effects on the levels of miRNAs targeting transcripts encoding key regulators of cell homeostasis.
The levels of tumor suppressor factors encoded by putative target transcripts of oncogenic miRNAs downregulated by resveratrol increase following resveratrol treatment
Although the absolute levels of miRNAs upregulated or downregulated by resveratrol as well as their relative activities on their target transcripts in SW480 cells cannot be definitely ascertained, the above results suggested that resveratrol treatment may change the levels of several of the factors encoded by transcripts targeted by these miRNAs ( Table 2) . We thus investigated the effects of resveratrol on several factors known to behave as tumor suppressors, such as PTEN and PDCD4, as well as on critical effectors of the TGF signaling pathway.
Indeed, the levels of TGF receptors type II and type I (TGFR2 and TGFR1, respectively)
increased by roughly 60% and 70%, respectively ( Figures 1A and 1C , respectively). The levels of both PTEN, a phosphatase targeting PI3K (Phosphoinositide 3-kinase), and PDCD4, a factor upregulated during apoptosis, also increased by roughly 60% (Figures 1A and 1B, respectively) .
The levels of E-CADHERIN, a component of adherens junctions implicated in the maintenance of epithelial phenotype, and of SMAD7, a negative regulator of TGF signaling, respectively increased by nearly 50% and 35% ( Figures 1B and 1D, respectively) . In contrast, the upregulation of SMAD3 following resveratrol treatment was almost neglectible (Figure 1C) , which may possibly arise from the fact that SMAD3 transcripts are also potentially targeted by five miRNAs upregulated by resveratrol, including miR-1 and miR-146b-5p, the two miRNAs which showed the greatest upregulation by resveratrol ( Table 1) . Nevertheless, resveratrol treatment of SW480 cells globally lead to the increase of the levels of effectors of TGF signaling pathway as well as of several tumor suppressor factors.
Resveratrol upregulates miR-663, a miRNA targeting TGF1 transcripts
The 3'-UTR of TGF1 is short (307 nt in length) and is potentially targeted by no more than 28 miRNAs, which probably results from the existence of multiple levels of regulation of the rate of TGF1 signaling. Remarkably, however, resveratrol upregulated one and only one of these miRNAs in SW480 cells, namely miR-663, a miRNA previously shown to be downregulated in hormone refractory prostate cancer cells [27] ( Table 1) . Of note, TGF1
behaves as a tumor promoter on advanced stages of tumorigenesis, due to its capability to enhance angiogenesis, epithelial-to-mesenchymal transition, cell motility and metastasis [11] [12] [13] .
Especially, it has been shown that increasing colorectal tumor stage correlates with higher TGF1 expression in tumor tissues [14] . We therefore double-checked the upregulation of miR-663 by resveratrol using RNase-protection assays. This experiment suggested that the levels of mature miR-663 in SW480 cells may increase by roughly 100% following resveratrol treatment (Figure 2) , a result in good agreement with those of miRNA micro-array experiments ( Table 1) .
Of note, the levels of miR-663 primary transcripts, namely pri-miR-663, increased 50% further, suggesting that resveratrol may also regulate the processing of miR-663 from its primary transcripts (Figure 2 ).
The effects of miR-663 on TGF1 transcripts were subsequently analyzed in SW480 cells transfected with either a control RNA (pre-miR-Control) or pre-miR-663 along with a construct containing the whole 307 nt-long 3'-UTR of TGF1 inserted downstream the luciferase gene in the pGL3-Control vector in sense or in antisense orientation. TGF1 3'-UTR namely contains five miR-663 target sites (TS) ( Figure 3A ) arranged in two sets of three and two overlapping sites, respectively (sites TS1 to TS3, starting at nt 8, and sites TS4 and TS5, starting at nt 43).
Pre-miR-663 reduced the luciferase activity produced from sense Luc-TGF1 construct by about 60%, while remaining without effects on antisense construct ( Figure 3B ). The lack of the first 41 nt of TGF1 3'-UTR, which contain the three first miR-663 sites (i.e., TS1 to TS3), in Luc-TGF-Del-663-1, or the mutation of the three same sites by replacing a few nt by the complementary nt in Luc-TGF-M663-1 ( Figure 3A) , still allowed a residual down-regulation of the luciferase activity of roughly 20%, while mutating the two last miR-663 sites (TS4 and TS5) in Luc-TGF-M663-2 still lead to about 50% decrease of the luciferase activity ( Figure   3B ). However, the luciferase activity produced from a construct bearing both sets of mutations (Luc-TGF-M663-1,2) remained essentially unaffected by resveratrol. Collectively, these results
suggest that miR-663 may target TGF1 transcripts in vivo. 
Resveratrol decreases
Discussion
Our study points to the importance of miRNA regulation in the modulation of the levels their strong oncogenic potentials, including miR-21 or miRNAs from the miR-17-92 cluster. This is an important result, for miR-21 for example is over-expressed in several cancers, including CRCs, gliomas, as well as breast, gastric, prostate, pancreas, lung, thyroid and cervical cancers [17] . MiR-21 has been shown to function as an onco-miR, due to its targeting of transcripts encoding key regulators of cell proliferation and apoptosis such as PTEN and PDCD4 [28] [29] [30] .
Especially, PDCD4 is downregulated in a number of cancers, and its suppression in lung and colorectal cancers is associated with poor patient prognosis [31, 32] . Indeed, the levels of these two anti-tumor factors increased following resveratrol treatment of SW480 cells. Also, the downregulation of both miR-103-1 and miR-103-2 by resveratrol may possibly be critical to its anti-metastatic effects. Namely, these miRNAs have been recently shown to induce epithelial-tomesenchymal transition by targeting Dicer1 transcripts [33] , in relation with the fact that a global reduction of miRNA abundance appears a general trait of human cancers, playing a causal role in the transformed phenotype [34] [35] [36] . Interestingly, the lower metastatic propensity in SW480 cells as compared with SW620 human colon cancer cells, both derived from the primary tumor and a metastasis of the same patient, respectively [37] , was associated with a lower level of expression of miR-103 [33] . Finally, we also show that the levels of several effectors of TGF pathway signaling, and especially TGFR1 and TGFR2, increase following resveratrol treatment in correlation with the downregulation of miRNAs whose consensus target sequences are present in their 3'-UTRs. This may be the reason why resveratrol favors the tumor suppressor, i.e., the cytostatic activity of TGF1 in epitheliums [11, 13] at the early stage of cancers. Altogether, the modification of the levels of no less than 48 miRNAs following resveratrol treatment of SW480 colon cancer cells, some well known to be oncogenic but several of them remaining essentially un-characterized at the present time, is likely to be critical for resveratrol protective effects.
Furthermore, epidemiological studies suggest that as many as 25% of all cancers may be due to chronic inflammation [38, 39] . As miR-21 in particular is induced by inflammation [40] , and resveratrol is known as an anti-inflammatory agent, the downregulation of miR-21 by resveratrol may be an important step in controlling cell proliferation and further tumorigenesis.
In this respect, it is important to note that TGF also functions as a purveyor of immune privilege. While beneficial in initiating and controlling immune responses and maintaining immune homeostasis, immunosuppressive pathways mediated by TGF may obscure immune surveillance mechanisms, resulting in failure to recognize or respond adequately to self, foreign, or tumor-associated antigens [41] . It will thus be important to investigate the possible links between the targeting of TGFR1 or SMAD3 and the development of local inflammation, especially considering that the maturation of miR-21 is increased upon TGF signaling in a SMAD3-dependent but SMAD4-independent pathway, with SMAD3 binding to miR-21
primary-transcript and interacting with the microprocessor complex [42] .
Among miRNAs upregulated by resveratrol, we identified miR-663, a miRNA previously shown to be down-regulated in hormone refractory prostate cancer cells [27] . We present evidence that miR-663 targets constructs containing TGF1-3'-UTR, and that the levels of TGF1 in SW480 cells are inversely correlated with the levels of miR-663. We also show that resveratrol decreases the expression of Luc-TGF1 constructs in a miR-663-dependent manner.
However, while resveratrol expectedly sharply decreased endogenous TGF1 levels in SW480 Of note, miR-663 has just been described as a tumor suppressor miRNA that induces mitotic catastrophe growth arrest in human gastric cancer cells [44] . While this paper do not provide the reader with a mechanistic explanation of this effect, it is tempting to speculate that the anti-tumor effects of miR-663 may be due, at least in part, to its effects on TGF1 and SMAD3 accumulation, given that TGF1 has been shown to promote invasion and metastasis of gastric cancer through its activation of TGFR1-ALK5/SMAD3 pathway [45] . The effects of miR-663 described here may thus be of primary importance, for TGF1 has been shown to enhance angiogenesis, epithelial-to-mesenchymal transition, cell motility and metastasis at later stages of cancers [11] [12] [13] . Especially, the expression of TGF1 in both tumor and plasma was found to be significantly higher in patients with metastasic colorectal cancer, and increasing colorectal tumor stage was correlated with higher TGF1 expression in tumor tissue [14] . In this respect, it should be emphasized that, in relation with the multiple levels of possible regulation of the rate of TGF signaling, the 307-nt long 3'-UTR of TGF1 transcripts represents a potential target for 28 miRNAs only. While two of these miRNAs have two putative target sites in TGF1 Furthermore, it has been proposed that an increase in the absolute number of mRNA targets may impact the balance and/or half-life of -free‖ miRNA, miRNA-RISC, and MiRNA-RISC-mRNA complexes [47] . Thus, given the dual role of TGF1 as both a tumor-suppressor at pre-malignant stage and promoter of metastasis at malignant stage [8, [11] [12] [13] , it would be interesting to determine if the impact of miR-663 on TGF1 transcripts may vary accordingly to the stage of tumor. Finally, as SMAD2 and SMAD3 phosphorylated at both linker and Cterminal regions transmit malignant TGF signaling in later stages of human CRC [48] , and as SMAD7 can act either as a tumor-promoter, by inhibiting the canonical TGF pathway, or a as tumor suppressor, especially by promoting the ubiquitination and thus the proteasomal degradation of -CATENIN, a key transducer of canonical WNT signaling [7, 49] , it is probable that the interactions between TGF signaling and miRNAs sensible to resveratrol, and especially miR-663, may be generally both dose-and context-dependent.
As a last remark, the fact that miR-663, miR-21 and TGF1 have been implicated in the regulation of cell proliferation, tumor apparition and development, metastasis formation and innate immunity, strongly suggests that the capability of resveratrol to behave at the same time as an anti-tumor, anti-metastatic, anti-proliferation and anti-inflammatory agent most probably arises from its effects on the expression of a small set of critical endogenous miRNAs having the abilities to impact the cell proteome globally.
Finally, miRNAs have the promise to become biomarkers for different stages of cancer, both for diagnosis and prognosis. Our analyses of microRNAs that change following resveratrol treatment of SW480 colon cancer cells showed that many of their putative target transcripts encode effectors of the TGFβ signaling pathway. The discovery that resveratrol may potentially allow to control the behavior of the TGF signaling pathway opens the possibility of using resveratrol in colon cancers where this pathway is impaired or work to favor metastasis.
Furthermore, using microRNA analyses turns out to be a powerful technique not only to classify tumors but also to identify the spectrum of genes where a certain drug/chemical might act. Thus, from our experiments, it starts to become clear that the use of resveratrol would be especially beneficial in the type of cancers where the TGFβ pathway is implicated. Of note, resveratrol use would have to be carefully correlated with the stages of cancers, knowing that TGFβ can have two faces, i.e. anti-and pro-metastatic.
In conclusion, further investigation of the effects of resveratrol on miRNA populations in tumors, and especially in CRCs, may allow to improve the diagnostic and prognostic of several types of cancers, as well as to optimize the use of this molecule as an anti-tumor agent.
Importantly, a critical attention will have to be given to the model organism. Namely, while resveratrol anticarcinogenic potential has been linked with data primarily from human cell culture systems, evidence that resveratrol can inhibit carcinogenesis in several organ sites emerged from results of cancer prevention and therapy studies in laboratory animal models [24] .
not always allow to predict accurately the molecular effects of resveratrol in human, especially when it comes to miRNAs.
Figure legends Values represent the mean ± standard deviation (n = 6). * and **, TGFβ1-treated significantly different from the corresponding Mock-treated, *, P < 0.03, **, P < 0.002; # and ##, Resveratroltreated significantly different from the corresponding Vehicle-treated, #, P < 0.03, ##, P < 0.005 (df = 10).
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